Medicare Part D

Is there a simple fix for the Part D discount program?A poll from the Biosimilars Council, a division of the Association for Accessible Medicines, has interesting findings about placing biosimilars and branded biologics on a level playing field to save money.
Potential CVS-Aetna merger: Key takeaways for health execsThe CVS Health-Aetna potential merger will have healthcare executives rethinking traditional industry competitors. Here’s why.
Study: Formularies may be key to alleviating opioid epidemicNew Yale University research offers stunning findings about drug formulary coverage and prescribing opioids.
Report: Community Pharmacy Has Broadened Scope of Services
Report: Community Pharmacy Has Broadened Scope of ServicesA new NCPA report highlights the role of community pharmacies.
Removing DIR Fees Could Save Billions
Removing DIR Fees Could Save BillionsA study commissioned by the NCPA shows the effect of DIR fees.
New Website Reveals DIR Fee Problems
New Website Reveals DIR Fee ProblemsNASP takes aim at DIR fees.
Are Rebates Responsible for Higher Drug Costs?A new study shows how the Medicare donut hole could be costing patients.
DIR Fees: What NCPA Wants from Part DIn a letter to the CMS, DIR fees take precedence
New Report: PBMs Push Drug Costs
New Report: PBMs Push Drug CostsAre PBMs responsible for higher drug prices or is something else to blame?
5 Ways to Improve Medicare Part DNCPA’s recommendations for improving the “increasingly complicated Part D marketplace.”